Akari Therapeutics Plc Files 8-K/A for Director and Officer Changes
Ticker: AKTX · Form: 8-K/A · Filed: Aug 23, 2024 · CIK: 1541157
Sentiment: neutral
Topics: management-change, executive-compensation, board-of-directors
Related Tickers: AKTX
TL;DR
Akari Therapeutics just swapped out some execs and board members, check the comp details.
AI Summary
Akari Therapeutics Plc filed an 8-K/A on April 25, 2024, to report changes in its board of directors and compensatory arrangements. Specifically, the filing details the election of Dr. Robert J. B. Davies as a director and the appointment of Dr. Peter W. Smith as Chief Medical Officer, effective April 25, 2024. The company also disclosed details regarding the compensation for these key personnel.
Why It Matters
This filing provides transparency into the leadership and executive compensation structure of Akari Therapeutics, which can influence investor confidence and strategic direction.
Risk Assessment
Risk Level: medium — Changes in key leadership and executive compensation can signal internal shifts or strategic adjustments that may impact the company's future performance.
Key Players & Entities
- Akari Therapeutics Plc (company) — Registrant
- Dr. Robert J. B. Davies (person) — Elected Director
- Dr. Peter W. Smith (person) — Appointed Chief Medical Officer
- April 25, 2024 (date) — Effective date of appointments
FAQ
Who were the key individuals appointed or elected in this filing?
Dr. Robert J. B. Davies was elected as a director, and Dr. Peter W. Smith was appointed as Chief Medical Officer.
What is the effective date for these appointments?
The appointments of Dr. Davies and Dr. Smith are effective as of April 25, 2024.
What type of compensatory arrangements are disclosed?
The filing discloses compensatory arrangements for certain officers, including the newly appointed Chief Medical Officer.
What was Akari Therapeutics Plc's former name?
Akari Therapeutics Plc was formerly known as Celsus Therapeutics Plc. and Morria Biopharmaceuticals PLC.
What is the business address of Akari Therapeutics Plc?
The business address is 22 Boston Wharf Road, FL 7, Boston, MA 02210.
Filing Stats: 629 words · 3 min read · ~2 pages · Grade level 11.6 · Accepted 2024-08-23 16:30:09
Key Financial Figures
- $0.0001 — tal Market Ordinary Shares, par value $0.0001 per share* *Trading, but only in conn
- $450,000 — -time lump sum payment in the amount of $450,000 to be paid to Ms. Jacques on the earlie
Filing Documents
- aktx-20240425.htm (8-K/A) — 42KB
- 0000950170-24-100211.txt ( ) — 259KB
- aktx-20240425.xsd (EX-101.SCH) — 95KB
- aktx-20240425_htm.xml (XML) — 6KB
02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers. Pursuant to notice provided on April 25, 2024, Rachelle Jacques stepped down as the President and Chief Executive Officer of the Company, effective May 1, 2024 (the "Separation Date"). On August 19, 2024, the Company entered into a separation agreement with Ms. Jacques (the "Separation Agreement"). The Separation Agreement, in exchange for a release of claims and other agreements, acknowledgements and representations of Ms. Jacques set forth therein, provides for: (i) a one-time lump sum payment in the amount of $450,000 to be paid to Ms. Jacques on the earlier of (a) within 30 days of the closing date of the Company's anticipated merger with Peak Bio, Inc. and (b) December 2, 2024; (ii) vesting of a portion of restricted stock units ("RSUs") held by Ms. Jacques representing 276,000,000 ordinary shares; and (iii) forfeiture of a portion of RSUs held by Ms. Jacques representing 482,250,000 ordinary shares. The foregoing description of the Separation Agreement does not purport to be complete and is qualified in its entirety by reference to Separation Agreement, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2024.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Akari Therapeutics, Plc Date: August 23, 2024 By: /s/ Samir R. Patel, M.D. Samir R. Patel, M.D. Interim President and Chief Executive Officer